Browse studies

Find your next paid study

27,295 recruiting studies available now

A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and…

Locally Advanced Solid TumorMetastatic Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nuvalent Inc.NCT06521554

Phase 1

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are blood cancers that affect certain white blood cells. Advanced forms of…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT07428707

Phase 3

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic…

Non-small Cell Lung Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT06345729

Observational

Preventing Financial Adversity Among Early-Stage Cancer Patients Through Unrestricted Cash (PAYMENT) Pilot Study

This clinical trial studies whether an unrestricted cash payment program can be used to improve financial and clinical outcomes in early-stage cancer patients …

Malignant Solid Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

Fred Hutchinson Cancer CenterNCT06771739

Phase 3

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metas…

Medulloblastoma

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Nationwide Children's HospitalNCT07291102

Health-Related Quality of Life and Clinical Utilization in Pediatric and Young Adult Patients With Hereditary Hemorrhagic Telangiectasia

This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Te…

Hereditary Haemorrhagic Telangiectasia (HHT)

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Ashley NelsonNCT07474428

Phase 1

An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to near…

Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation

Estimated

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT05099172

Phase 1

A Phase 1/2a, Multi-center, Open-label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of PBGENE-DMD in Participants With Duchenne Muscular Dystrophy (FUNCTION-DMD)

The purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations a…

Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Precision BioSciences, Inc.NCT07429240

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times…

Essential Tremor, Movement DisordersEssential TremorEssential Tremor-plus

Estimated

~$10 – $1,125

Actual pay is set by the research site.

CND Life SciencesNCT07428447

Observational

Myofunctional Therapy for Obstructive Sleep Apnea

The purpose of this study is to explore a new way to examine the function of the muscles using a technique called high-resolution manometry. The study will enr…

Obstructive Sleep Apnea

Estimated

~$10 – $750

Actual pay is set by the research site.

University of MinnesotaNCT07301125

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and i…

Radiographic Axial Spondyloarthritis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Merck Sharp & Dohme LLCNCT07133633

Phase 1

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Advanced Solid Tumors

Estimated

~$150 – $4,200

Actual pay is set by the research site.

DualityBio Inc.NCT05914116